Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease

Circulation

Volumn 98, Issue 15, 1998, Pages 1487-1494

  Holvoet, Paul ^a   Vanhaecke, Johan ^b   Janssens, Stefaan ^b   Van De Werf, Frans ^b   Collen, Désiré ^b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b NONE

Author keywords

Angina; Coronary disease; Diagnosis; Lipoproteins; Plaque

Indexed keywords

C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; OXIDIZED LOW DENSITY LIPOPROTEIN; TROPONIN I;

ACUTE HEART INFARCTION; ADULT; AGED; ANGINA PECTORIS; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; HEART MUSCLE ISCHEMIA; HEART TRANSPLANTATION; HUMAN; LIPID OXIDATION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; UNSTABLE ANGINA PECTORIS;

EID: 0032514728     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.98.15.1487     Document Type: Article

References (40)

1. Gerrity RG. The role of the monocyte in atherogenesis, I: transition of blood-borne monocytes into foam cells in fatty lesions. Am J Pathol. 1981;103:181-190.
2. Schaffner T, Taylor K, Bartucci EJ, Fischer-Dzoga K, Beeson JH, Glagov S, Wissler, RW. Arterial foam cells with distinctive immunomorphologic and histochemical features of macrophages. Am J Pathol. 1980;100: 57-80.
3. Brown MS, Goldstein JL. Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. Annu Rev Biochem. 1983;52:223-261.
4. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809.
5. Heery JM, Kozak M, Stafforini DM, Jones DA, Zimmerman GA, McIntyre TM, Prescott SM. Oxidatively modified LDL contains phospholipids with platelet-activating factor-like activity and stimulates the growth of smooth muscle cells. J Clin Invest. 1995;96:2322-2330.
6. Penn MS, Chisolm GM. Oxidized lipoproteins, altered cell function and atherosclerosis. Atherosclerosis. 1994;108:S21-S29.
7. Steinberg D. Clinical trails of antioxidants in atherosclerosis: are we doing the right thing? Lancet. 1995;346:36-38.
8. Holvoet P, Stassen JM, Van Cleemput J, Collen D, Vanhaecke J. Correlation between oxidized low density lipoproteins and coronary artery disease in heart transplant patients. Arterioscler Thromb Vasc Biol. 1998; 18:100-107.
9. Holvoet P, Perez G, Zhao Z, Brouwers E, Bernar H, Collen D. Malondialdehyde-modified low density lipoproteins in patients with atherosclerotic disease. J Clin Invest. 1995;95:2611-2619.
10. Adams JE, 3d, Bodor GS, Davila-Roman VG, Delmez JA, Apple FS, Ladenson JH, Jaffe AS. Cardiac troponin: a marker with high specificity for cardiac injury. Circulation. 1993;88:101-106.
11. Antman EM, Tanasijevic MJ, Thompson B, Schactman M, McCabe CH, Cannon CP, Fischer GA, Fung AY, Thompson C, Wybenga D, Braunwald E. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med. 1996;335:1388-1389.
12. Oltrona L, Merlini PA, Pezzano A. C-reactive protein and serum amyloid A protein in unstable angina. N Engl J Med. 1995;332:399-400.
13. Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human sera. J Clin Invest. 1995;34:1345-1353.
14. Haberland MD, Fogelman AM, Edwards PA. Specificity of receptor-mediated recognition of malondialdehyde-modified low density lipoproteins. Proc Natl Acad Sci U S A. 1982;79:1712-1716.
15. Steinbrecher UP. Oxidation of low density lipoprotein results in derivatization of lysine residues of apolipoprotein B by lipid peroxide decomposition products. J Biol Chem. 1987;262:3603-3608.
16. Holvoet P, Donck J, Landeloos M, Brouwers E, Luijtens K, Arnout J, Lesaffre E, Vanrenterghem Y, Collen D. Correlation between oxidized low density lipoproteins and von Willebrand factor in chronic renal failure. Thromb Haemost. 1996;76:663-669.
17. Holvoet P, Collen D. βVLDL hypercholesterolemia relative to LDL hypercholesterolemia is associated with higher levels of oxidized lipoproteins and a more rapid progression of coronary atherosclerosis in rabbits. Arterioscler Thromb Vass Biol. 1997;17:2376-2382.
18. Holvoet P, Theilmeier G, Shivalkar B, Flameng W, Collen D. LDL hypercholesterolemia is associated with accumulation of oxidized LDL, atherosclerotic plaque growth, and compensatory vessel enlargement in coronary arteries of miniature pigs. Arterioscler Thromb Vasc Biol. 1998; 18:415-422.
19. Declerck PJ, Mombaerts P, Holvoet P, De Mol M, Collen D. Fibrinolytic response and fibrin fragment D-dimer levels in patients with deep vein thrombosis. Thromb Haemost. 1987;58:1024-1029.
20. Hoffmeister HM, Jur M, Wendel HP, Heller W, Seipel L. Alterations of coagulation and fibrinolytic and kallikrein-kinin systems in the acute and post-acute phases in patients with unstable angina pectoris. Circulation. 1995;91:2520-2527.
21. Esterbauer H, Jurgens G, Quehenberger Q, Koller E. Autooxidation of human low density lipoprotein: loss of polyunsaturated fatty acids and vitamin E and generation of aldehydes. J Lipid Res. 1987;28:495-509.
22. Steinbrecher UP, Parthasarathy S, Leake DS, Witztum JL, Steinberg D. Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci U S A. 1984;81:3883-3887.
23. Parthasarathy S, Wieland E, Steinberg D. A role for endothelial cell lipoxygenase in the oxidative modification of low density lipoprotein. Proc Natl Acad Sci U S A. 1989;86:1046-1050.
24. Ravalli S, Marboe CC, D'Agati VD, Michler RE, Sigal E, Cannon PJ. Immunohistochemical demonstration of 15-lipoxygenase in transplant coronary artery disease. Arterioscler Thromb Vasc Biol. 1995;15:340-348.
25. Folcik VA, Nivar-Aristy RA, Krajewski LP, Cathcart MK. Lipoxygenase contributes to the oxidation of lipids in human atherosclerotic plaques. J Clin Invest. 1995;96:504-510.
26. Sparrow CP, Olszewski J. Cellular oxidative modification of low density lipoprotein does not require lipoxygenases. Proc Natl Acad Sci U S A. 1992;89:128-131.
27. 2 in human atherosclerotic plaques. Atherosclerosis. 1995;118:173-181.
28. Aviram M, Maor I. Phospholipase D-modified low density lipoprotein is taken up by macrophages at increased rate: a possible role for phosphatidic acid. J Clin Invest. 1993;91:1942-1952.
29. Savenkova ML, Mueller DM, Heinecke JW. Tyrosyl radical generated by myeloperoxidase is a physiological catalyst for the initiation of lipid peroxidation in low density lipoprotein. J Biol Chem. 1994;269: 20394-20400.
30. Steinberg D. Lewis A. Conner Memorial Lecture. Oxidative modification of LDL and atherogenesis. Circulation. 1997;95:1062-1071.
31. Holvoet P, Collen D. Thrombosis and atherosclerosis. Curr Opin Lipidol. 1997;8:320-328.
32. Murugesan G, Chisolm GM, Fox PL. Oxidized low density lipoprotein inhibits the migration of aortic endothelial cells in vitro. J Cell Biol. 1993;120:1011-1019.
33. Chen CH, Nguyen HH, Weilbaecher D, Luo S, Gotto AM Jr, Henry PD. Basic growth factor reverses atherosclerotic impairment of human coronary angiogenesis-like responses in vitro. Atherosclerosis. 1995;116: 261-268.
34. Haberland ME, Olch CL, Fogelman AM. Role of lysines in mediating interaction of modified low density lipoproteins with the scavenger receptor of human monocyte macrophages. J Biol Chem. 1984;259: 11305-12311.
35. Fogelman MA, Shechter I, Seager J, Hokom M, Child JS, Edwards PA. Malondialdehyde modification of low density lipoproteins leads to cholesterylesters accumulation in human monocyte-macrophages. Proc Natl Acad Sci U S A. 1980;77:2214-2218.
36. Hoff HF, O'Neill J, Chisolm III GM, Cole TB, Quehenberger O, Esterbauer H, Jürgens G. Modification of low density lipoprotein with 4-hydroxynonenal induces uptake by macrophages. Arteriosclerosis. 1989;9:538-549.
37. Farber HW, Barnett HF. Differences in prostaglandin metabolism in cultured aortic and pulmonary arterial endothelial cells exposed to acute and chronic hypoxia. Circ Res. 1991;68:1446-1457.
38. 2-isoprostanes) are formed in situ on phospholipids. Proc Natl Acad Sci U S A. 1992;89:10721-10725.
39. 2-isoprostanes) in plasma of low density-lipoprotein exposed to oxidative stress in vitro. J Clin Invest. 1994;93:998-1004.
40. Hammer A, Kager G, Dohr G, Rabl H, Ghassempur I, Jürgens G. Generation, characterization, and histochemical application of monoclonal antibodies selectively recognizing oxidatively modified apoB-containing serum lipoproteins. Arterioscler Thromb Vasc Biol. 1995;15: 704-713.